Every compound we carry is backed by published research. Below you'll find curated peer-reviewed studies and clinical literature for each peptide — sourced directly from PubMed and the National Institutes of Health.
A precision 80 mg recovery blend: 50 mg GHK-Cu for tissue remodelling and collagen synthesis, 10 mg BPC-157 for tendon/gut repair, 10 mg TB-500 for systemic recovery, and 10 mg KPV for anti-inflammatory signalling via the α-MSH pathway.
Body Protection Compound-157 is a pentadecapeptide derived from human gastric juice. Research suggests it promotes tendon healing, nerve regeneration, and gut mucosal repair through angiogenic and cytoprotective pathways.
TB-500 is the synthetic form of the active region of Thymosin β4, a naturally occurring peptide that plays a key role in actin regulation, cell migration, wound healing, and cardioprotection.
A synergistic combination of BPC-157 and TB-500, targeting complementary healing pathways — BPC-157 for tendon/nerve/gut repair and TB-500 for actin remodelling and cardiac protection. See individual studies for each component above.
CJC-1295 is a long-acting synthetic analogue of growth hormone-releasing hormone (GHRH). Clinical studies demonstrate dose-dependent increases in GH and IGF-1 levels with preserved pulsatile secretion.
Ipamorelin is a selective pentapeptide GH secretagogue that stimulates GH release without significantly affecting cortisol or ACTH — a key differentiator from other GH secretagogues.
Sermorelin is a 29 amino-acid analogue of GHRH that stimulates endogenous GH secretion from the anterior pituitary. Studied extensively in both paediatric GH deficiency and adult anti-aging contexts.
Tesamorelin (Egrifta™) is an FDA-approved GHRH analog clinically proven to reduce visceral adipose tissue. Phase III trials demonstrated significant VAT reduction over 26 weeks.
Retatrutide is a novel triple agonist targeting GLP-1R, GIPR, and GCGR simultaneously. Phase II trials achieved up to 24.2% mean weight loss over 48 weeks — among the highest recorded for any obesity pharmacotherapy.
Semaglutide is a GLP-1 receptor agonist with a ~160-hour half-life allowing once-weekly dosing. The STEP 1 trial demonstrated 14.9% mean weight loss versus 2.4% placebo over 68 weeks.
Tirzepatide (Mounjaro™) is a dual GIP/GLP-1 receptor co-agonist. Clinical trials show superior glycaemic control and weight reduction versus selective GLP-1 agonists, with additional benefits for hepatic steatosis and sleep apnea.
AOD9604 is a synthetic analogue of the C-terminal lipolytic domain of human growth hormone. It stimulates fat oxidation and lipolysis without the diabetogenic effects of full-length hGH.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Cu²⁺) is a naturally occurring copper-binding tripeptide that stimulates collagen synthesis, activates metalloproteinases for tissue remodelling, and accelerates wound healing.
NAD⁺ (Nicotinamide Adenine Dinucleotide) is a coenzyme central to cellular energy metabolism and DNA repair. Levels decline significantly with age, and clinical supplementation trials show it is safe and effective at restoring NAD⁺ metabolism.
Glutathione (GSH) is the body's master antioxidant, critical for neutralising reactive oxygen species, supporting liver detoxification, and modulating immune function. Depletion is associated with aging and chronic disease.
Epithalon (AEDG) is a tetrapeptide derived from the pineal gland. Research demonstrates it induces telomerase activity, extends telomere length in human cells, and restores circadian melatonin secretion in aged primates.
Semax is an ACTH(4-10) analogue that stimulates BDNF and NGF expression in the brain. Clinical use in Russia for ischaemic stroke rehabilitation; research supports cognitive enhancement and neuroprotective effects.
Selank is a synthetic heptapeptide with anxiolytic and nootropic properties. It modulates GABA receptors and inhibits enkephalin degradation, producing anti-anxiety effects without the sedation or dependence of benzodiazepines.
SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, improving bioenergetics and protecting against oxidative damage in cardiomyocytes.
LL-37 is the only human cathelicidin antimicrobial peptide, with broad-spectrum antimicrobial, anti-biofilm, and immunomodulatory activity. In vivo studies show it significantly improves re-epithelialization and granulation tissue formation in wounds.
KPV (Lys-Pro-Val) is a C-terminal tripeptide of α-MSH with potent anti-inflammatory properties. It acts via PepT1 to inhibit NF-κB and MAP kinase signalling, reducing pro-inflammatory cytokines in models of colitis and IBD.
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist. FDA-approved as Vyleesi™ for HSDD in premenopausal women. Clinical trials demonstrate significant improvements in sexual desire and arousal.